These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38424421)

  • 1. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy.
    Mesquita FP; Lima LB; da Silva EL; Souza PFN; de Moraes MEA; Burbano RMR; Montenegro RC
    Curr Protein Pept Sci; 2024; 25(7):539-552. PubMed ID: 38424421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase expression in small-cell lung cancer.
    Kondoh C; Horio Y; Hayashi Y; Ebi H; Hida T; Hasegawa Y; Yatabe Y
    Histopathology; 2019 Jul; 75(1):20-28. PubMed ID: 30790327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.
    Rosas G; Ruiz R; Araujo JM; Pinto JA; Mas L
    Crit Rev Oncol Hematol; 2019 Apr; 136():48-55. PubMed ID: 30878128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of anaplastic lymphoma kinase rearrangement in early-stage lung cancer: Analysis of a nationwide Japanese database.
    Matsuura Y; Mun M; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
    J Surg Oncol; 2023 Oct; 128(5):916-924. PubMed ID: 37403534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
    Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
    Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
    Zhao Z; Verma V; Zhang M
    Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in non-small cell lung cancer patients from eastern India.
    Mohapatra PR; Sahoo S; Bhuniya S; Panigrahi MK; Majumdar SKD; Mishra P; Patra S
    J Cancer Res Ther; 2020; 16(4):850-854. PubMed ID: 32930129
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kaur V; Zadeh S
    WMJ; 2024 Sep; 123(4):315-319. PubMed ID: 39284095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.
    Wang YW; Tu PH; Lin KT; Lin SC; Ko JY; Jou YS
    Neoplasia; 2011 Aug; 13(8):704-15. PubMed ID: 21847362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma.
    Matsuura Y; Ninomiya H; Ichinose J; Nakao M; Okumura S; Nishio M; Mun M
    J Thorac Cardiovasc Surg; 2022 Feb; 163(2):441-451.e1. PubMed ID: 33131892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
    Rosenbaum JN; Bloom R; Forys JT; Hiken J; Armstrong JR; Branson J; McNulty S; Velu PD; Pepin K; Abel H; Cottrell CE; Pfeifer JD; Kulkarni S; Govindan R; Konnick EQ; Lockwood CM; Duncavage EJ
    Mod Pathol; 2018 May; 31(5):791-808. PubMed ID: 29327716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.
    Aras G; Kanmaz ZD; Tuncay E; Çetinkaya E; Yentürk E; Kocatürk C; Öz B; Çermik TF; Purisa S
    Tumori; 2019 Dec; 105(6):501-508. PubMed ID: 31910789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.